BioCentury
ARTICLE | Company News

NICE recommends Jazz's Vyxeos for AML

November 9, 2018 7:15 PM UTC

The U.K.'s NICE issued a final appraisal determination (FAD) recommending Vyxeos daunorubicin/cytarabine to treat adults with newly diagnosed therapy-related acute myelogenous leukemia (AML) or AML with myelodysplasia-related changes...

BCIQ Company Profiles

Jazz Pharmaceuticals plc